InvestorsHub Logo
Followers 35
Posts 1393
Boards Moderated 0
Alias Born 09/09/2009

Re: None

Tuesday, 04/22/2014 12:55:36 PM

Tuesday, April 22, 2014 12:55:36 PM

Post# of 144814
Nuvilex, Inc. Applying for Orphan Drug Status to Market Pancreatic Cancer Treatment Without Competition

Nuvilex, Inc. Could Obtain FDA Accelerated Approval After Phase 2b Clinical Trial

we are moving rapidly toward 2b trial.....

and this should put to rest any concerns about the patents....


While there are currently long-term patents on Nuvilex's pancreatic cancer treatment, receiving Orphan Drug status will allow the Maryland biotech firm to exclusively market the Cell-in-a-Box® technology combined with ifosfamide long after those patents expire.

bull
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PMCB News